Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 30;11(11):CD007824.
doi: 10.1002/14651858.CD007824.pub2.

Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts

Uday K Bhatt  1 , M N Abdul Karim, Jeremy I Prydal, Senthil V Maharajan, Usama Fares
Affiliations

Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts

Uday K Bhatt et al. Cochrane Database Syst Rev. .

Abstract

Background: Ocular herpes is a viral infection of the eye caused by the herpes simplex virus (HSV), a double-stranded DNA virus. Corneal scarring caused by herpes simplex keratitis (HSK) is the leading infectious cause of penetrating corneal graft in high-income countries. Acyclovir is an antiviral drug known to have a protective effect against recurrences in herpetic eye disease. While there are some studies which have evaluated the effects of intervention with oral antiviral in preventing such recurrences in people with corneal grafts, a systematic review of all comparative clinical trials has not been previously undertaken.

Objectives: To assess the efficacy of oral antivirals such as acyclovir in any dosage when taken for six months or more, in preventing recurrence of herpetic keratitis in people having corneal graft surgery for herpetic keratitis.

Search methods: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 5), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2016), Embase (January 1980 to June 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 1 June 2016. We handsearched conference proceedings and contacted authors of the included studies and researchers active in the field.

Selection criteria: We included randomised controlled trials (RCTs). People enrolled in these trials had corneal grafts for HSK. The intervention was oral antivirals for six months or more following the corneal graft surgery, and this was compared to no treatment or placebo.

Data collection and analysis: Two review authors independently assessed trial quality and extracted data. We contacted trial investigators for any clarification or missing information. We graded the certainty of the evidence using GRADE.

Main results: We included three trials, involving 126 participants, comparing the use of oral acyclovir to no treatment or placebo. Two studies were conducted in single centres in Turkey and the USA, and one was multi-centred in the Netherlands. In general, the studies were poorly reported and it was difficult to judge the extent to which bias had been avoided.Oral acyclovir may reduce the risk of recurrence of herpetic keratitis (risk ratio (RR) 0.29, 95% confidence interval (CI) 0.13 to 0.64, 126 people, low-certainty evidence). Based on data from the included trials, this corresponds to approximately 23 fewer cases of HSK recurrence (95% CI 29 fewer cases to 12 fewer cases) per 100 corneal graft operations if oral acyclovir is used.Oral acyclovir may reduce the risk of graft failure (RR 0.40, 95% CI 0.16 to 0.97, 126 people, low-certainty evidence). Based on data from the included trials, this corresponds to approximately 13 fewer cases of graft failure (95% CI 18 fewer cases to 1 fewer cases) per 100 corneal graft operations if oral acyclovir is used.None of the studies reported any serious side effects of the antivirals necessitating stoppage or change. None of the trials reported outcomes over the long term (more than two years) or any data on quality of life.

Authors' conclusions: Compared to placebo or to no treatment, oral antiviral (acyclovir) may reduce the risk of recurrence of herpetic keratitis in the first 12 months in eyes that have undergone corneal graft surgery.

PubMed Disclaimer

Conflict of interest statement

UB: None known AK: None known JP: None known SVM: None known UF: None known

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Akova 1999 {published data only}
    1. Akova YA, Onat M, Duman S. Efficacy of low‐dose and long‐term oral acyclovir therapy after penetrating keratoplasty for herpes simplex keratitis. Ocular Immunology and Inflammation 1999; Vol. 7, issue 1:51‐60. - PubMed
Foster 1992 {published data only}
    1. Barney NP, Foster CS. A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea 1994;13(3):232‐6. - PubMed
    1. Foster CS, Barney NP. Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis. Documenta Ophthalmologica 1992; Vol. 80, issue 4:363‐9. - PubMed
Van Rooij 2003 {published data only}
    1. Rooij J, Rijneveld WJ, Remeijer L, Volker‐Dieben HJ, Eggink CA, Geerards AJ, et al. Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo‐controlled multicenter trial. Ophthalmology 2003; Vol. 110, issue 10:1916‐9. - PubMed

References to studies excluded from this review

Jansen 2009 {published data only}
    1. Jansen AF, Rijneveld WJ, Remeijer L, Volker‐Dieben HJ, Eggink CA, Geerards AJ, et al. Five‐year follow‐up on the effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis. Cornea 2009;28(8):843‐5. - PubMed

Additional references

Cobo 1980
    1. Cobo LM, Coster DJ, Rice NS, Jones BR. Prognosis and management of corneal transplantation for herpetic keratitis. Archives of Ophthalmology 1980; Vol. 98, issue 10:1755‐9. - PubMed
Cook 1991
    1. Cook SD, Hill JH. Herpes simplex virus: molecular biology and the possibility of corneal latency. Survey of Ophthalmology 1991;36(2):140‐8. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Ficker 1988
    1. Ficker LA, Kirkness CM, Rice NS, Steele AD. Longterm prognosis for corneal grafting in herpes simplex keratitis. Eye 1988; Vol. 2, issue Pt 4:400‐8. - PubMed
Ficker 1989
    1. Ficker LA, Kirkness CM, Rice NS, Steele AD. The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. Ophthalmology 1989; Vol. 96, issue 11:1587‐96. - PubMed
Garcia 2007
    1. Garcia DD, Farjo Q, Musch DC, Sugar A. Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea 2007;26(8):930‐4. - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
HEDS 1998
    1. Anonymous. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. New England Journal of Medicine 1998; Vol. 339, issue 5:300‐6. - PubMed
Higgins 2011a
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kimberlin 2007
    1. Kimberlin DW, Whitley RJ. Antiviral therapy of HSV‐1 and ‐2. In: Arvin A, Campadelli‐Fiume G, Mocarski E editor(s). Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007. - PubMed
Kohl 1985
    1. Kohl S. Herpes simplex virus immunology: problems, progress, and promises. Journal of Infectious Diseases 1985;152(3):435‐40. - PubMed
Langenham 2013
    1. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schünemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;2:81. - PMC - PubMed
Liesegang 1991
    1. Liesegang TJ. A community study of ocular herpes simplex. Current Eye Research 1991; Vol. 10, issue Suppl:111‐5. - PubMed
Liesegang 2001
    1. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001; Vol. 20, issue 1:1‐13. - PubMed
Moyes 1994
    1. Moyes AL, Sugar A, Musch DC, Barnes RD. Antiviral therapy after penetrating keratoplasty for herpes simplex keratitis. Archives of Ophthalmology 1994; Vol. 112, issue 5:601‐7. - PubMed
Pepose 1991
    1. Pepose JS. Herpes simplex keratitis: role of viral infection versus immune response. Survey of Ophthalmology 1991; Vol. 35, issue 5:345‐52. - PubMed
Remeijer 2004
    1. Remeijer L, Osterhaus A, Verjans G. Human herpes simplex virus keratitis: the pathogenesis revisited. Ocular Immunology and Inflammation 2004; Vol. 12, issue 4:255‐85. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Shimomura 2007
    1. Shimomura Y, Deai T, Fukuda M, Higaki S, Hooper LC, Hayashi K. Corneal buttons obtained from patients with HSK harbor high copy numbers of the HSV genome. Cornea 2007; Vol. 26, issue 2:190‐3. - PubMed
Simon 1996
    1. Simon AL, Pavan‐Langstan D. Long‐term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with or without grafts. Ophthalmoogy 1996;103(9):404‐5. - PubMed
Tambasco 1999
    1. Tambasco FP, Cohen EJ, Nguyen LH, Rapuano CJ, Laibson PR. Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Archives of Ophthalmology 1999; Vol. 117, issue 4:445‐9. - PubMed
Van Rooij 1995
    1. Rooij J, Rijneveld WJ, Remeijer LJ, Beekhuis WH. A retrospective study on the effectiveness of oral acyclovir to prevent herpes simplex recurrence in corneal grafts. European Journal of Ophthalmology 1995; Vol. 5, issue 4:214‐8. - PubMed
White 2014
    1. White ML, Chodosh J. Herpes simplex virus keratitis: a treatment guideline ‐ 2014. www.aao.org/clinical‐statement/herpes‐simplex‐virus‐keratitis‐treatment‐... (accessed 19 January 2015).

References to other published versions of this review

Bhatt 2009
    1. Bhatt UK, Abdul Karim M, Prydal JI. Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007824] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources